Revenue segments as reported by the company.

Transcatheter Aortic Valve Replacement

Transcatheter Mitral and Tricuspid Therapies

Surgical Structural Heart

Critical Care

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative expenses

Research and development expenses

Intellectual property litigation expenses, net

Change in fair value of contingent consideration liabilities

Special charges

Restructuring expenses

Other operating expenses, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Edwards Lifesciences

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring systems measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Edwards Lifesciences projects robust sales growth amidst market advancements

Edwards Lifesciences showcased strong sales growth and financial performance in Q4 2022. Despite challenges like FX impacts and spotty backlog, the company remains confident in its growth outlook. Encouraging opportunities lie in TMTT and Surgical Structural Heart segments for future expansion.

Edwards Lifesciences reports robust Q1 sales, eyes global expansion

Edwards Lifesciences delivered strong sales performance in Q1, driven by key product segments and global growth.
The company faces challenges in managing expenses and navigating competitive dynamics, particularly in Japan.
Opportunities lie in continued market growth, product innovation, and efficiency enhancements across operations.
Overall, Edwards Lifesciences remains well-positioned for growth and market leadership in the cardiovascular space.

Edwards Lifesciences exceeds Q2 expectations, raises full-year guidance

Edwards Lifesciences delivered strong Q2 results, raising full year guidance and highlighting growth in key segments. While facing challenges like seasonal impacts and market recovery issues, the company remains focused on innovation and market expansion.

Edwards Lifesciences excels in Q3, poised for diversified growth

Edwards Lifesciences delivered a strong Q3 performance with growth across key segments and a positive outlook for 2023.
The company's focus on innovation, differentiated sales strategies, and patient-centric initiatives position it well for future growth.
Challenges in pricing dynamics and market competition require strategic management, while opportunities in diverse therapies and patient activation initiatives offer avenues for expansion.
Overall, Edwards Lifesciences maintains a solid financial position, supported by a robust balance sheet and a commitment to long-term growth.

Edwards Lifesciences posts strong Q4 results, eyes global growth opportunities

Edwards Lifesciences' Q4 2023 performance reflects solid financial health and strategic investments for future growth. Despite facing challenges such as rising expenses and competitive pressures, the company is well-positioned to capitalize on opportunities through innovation and market expansion.

Edwards Lifesciences reports robust Q1 sales growth and outlook

Edwards Lifesciences shows strong sales growth across key segments and raises 2024 outlook.
Investments in transcatheter platforms and positive milestones drive sustainable growth.
Challenges include managing increased expenses and ensuring center readiness for new therapies.
Opportunities in AI implementation, patient care initiatives, and diversified growth potential.

Edwards Lifesciences reports strong Q3 performance and strategic growth focus

Edwards Lifesciences delivered robust Q3 results driven by TAVR and TMTT growth, showcasing resilience and innovation.
While facing challenges in certain markets like Japan, Edwards maintains a strong competitive position and strategic focus on long-term growth.
The company's acquisitions, product advancements, and maintained guidance reflect a commitment to expansion and market leadership.
With opportunities in innovation and global expansion, Edwards is poised for continued growth and success in the medical technology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Edwards Lifesciences (EW) expects to report underlying sales growth in the mid-single-digit range for 2022, banking on market growth and the adoption of premium technologies.

Edwards Lifesciences (EW) Rides on Innovation Amid Rising Costs

Danaher

Humana

Pfizer

UnitedHealth Group

Cramer said that healthcare stocks have stayed relatively steady this year because they tend to be recession-resistant stocks.

Jim Cramer recommends these 5 healthcare stocks in 2023

Intuitive Surgical

We believe that Intuitive Surgical stock and Edwards Lifesciences stock, in the medical devices industry, will likely give similar returns over the next three years. Intuitive Surgical﻿﻿ is trading at a comparatively higher valuation of 15.8x trailing revenues, compared to.

Pick Either Intuitive Surgical Or Its Industry Peer – Both May Offer Similar Returns

IRVINE, Calif. , Dec. 8, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) will discuss the company's strategy for longer-term growth, provide an update on its technology pipeline and share its financial guidance1 today during its annual investor conference.

EDWARDS LIFESCIENCES OUTLINES GROWTH STRATEGY AT ANNUAL INVESTOR CONFERENCE

IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced that following regular succession planning discussions with the Board of Directors, Edwards' chairman and CEO, Michael A.

EDWARDS LIFESCIENCES ANNOUNCES CEO SUCCESSION PLAN

AbbVie

Johnson & Johnson

Eli Lilly

Merck

Walgreens

Amid rising concerns about the state of the global economy, rising inflation, central bank interest rate hikes and increased Covid-19 restrictions in China, marked indexes were mixed on Wednesday morning.

Gurus Prescribed These Health Care Stocks in the 3rd Quarter

BeiGene

Bio-Rad Laboratories

Catalent

DexCom

Gilead Sciences

Moderna

Seagen

West Pharmaceutical Services

The healthcare sector has gained momentum following the COVID-19 pandemic. Several companies gained early regulatory approval for developing COVID-19 drugs and distributing vaccines.

These Are the Five Best and Worst Performing Healthcare Stocks in October 2022

LONDON , Nov. 27, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced that one-year results on patients treated in the single-arm, prospective, global, multi-center TRISCEND study of the company's EVOQUE transcatheter tricuspid valve replacement system demonstrated favorable safety, efficacy and quality-of-life outcomes. The data were presented during the late-breaking trials session at PCR London Valves 2022.

EDWARDS ANNOUNCES ONE-YEAR DATA ON TRANSFEMORAL TRANSCATHETER TRICUSPID VALVE REPLACEMENT

Baxter

Centene

CVS Health

Medtronic

Zoetis

Zoetis and Medtronic are among the healthcare stocks with the most room to rise, according to Wall Street analysts' average price targets.

6 Healthcare Stocks With Room to Climb

Avis Budget Group

Carlisle Companies

DoorDash

Halliburton

Royal Caribbean Cruises

SVB Financial Group

Schlumberger

The S&P 500 recovered in October, gaining almost 8%, but it is still down about 18% year to date.

These Were The Five Best And Worst Performing Large-Cap Stocks in October 2022

Heart disease equipment maker Edwards Life Sciences (NYSE: EW) stock has fallen (-46%) on the year after a disastrous reaction to its Q3 2022 earnings report.

Edwards Life Sciences Stock Disaster Could Be Your Bounty

IRVINE, Calif. , Nov. 1, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced that it has executed an accelerated share repurchase agreement ("ASR") to repurchase $750 million of Edwards' common stock.

EDWARDS LIFESCIENCES ANNOUNCES $750 MILLION ACCELERATED SHARE REPURCHASE

Amazon

Alibaba

5 Broadly Held Guru Stocks Trading at a Discount on Halloween

Edwards Lifesciences has seen shares cut nearly in half from the highs of last year. This is mostly in response to higher interest rates and an overreaction seen towards the upside last year.

Edwards Lifesciences: Opening My Heart

Edwards Lifesciences (EW) continues to register strong momentum in TMTT on a portfolio of differentiated therapies, positive pivotal trial results and favorable real-world clinical outcomes.

Edwards Lifesciences (EW) Q3 Earnings Miss, Margins Rise

Did investors overreact to the company's miss?

Why Edwards Lifesciences Stock Crashed 16% Today

Edwards Lifesciences says quarterly sales for its transcatheter aortic valve replacement rose 1% but were impacted by, among other things, 'persistent U.S. hospital staffing shortages.'

Edwards Lifesciences Stock Slumps on Guidance Cut

Edwards Lifesciences Corp (NYSE:EW ) Q3 2022 Earnings Conference Call October 27, 2022 5:00 PM ET Company Participants Mark Wilterding - VP, IR Michael Mussallem - Chairman & CEO Scott Ullem - Corporate VP & CFO Bernard Zovighian - Corporate VP, Transcatheter Mitral & Tricuspid Therapies Daveen Chopra - Corporate VP, Surgical Heart Valve Therapies Larry Wood - Corporate VP, Transcatheter Aortic Valve Replacement Conference Call Participants Lawrence Biegelsen - Wells Fargo Securities Robert Marcus - JPMorgan Chase & Co. Joshua Jennings - Cowen and Company Joanne Wuensch - Citigroup Richard Newitter - Truist Securities Frederick Wise - Stifel, Nicolaus & Company Cecilia Furlong - Morgan Stanley Philip Chickering - Deutsche Bank Vijay Kumar - Evercore ISI Travis Steed - Bank of America Merrill Lynch Adam Maeder - Piper Sandler & Co. Operator Good afternoon, and welcome to the Edwards Lifesciences Third Quarter 2022 Results Conference Call. [Operator Instructions].

Edwards Lifesciences Corp (EW) Q3 2022 Earnings Call Transcript

Edwards Lifesciences (EW) delivered earnings and revenue surprises of -1.61% and 1.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Edwards Lifesciences (EW) Lags Q3 Earnings and Revenue Estimates

Edwards Lifesciences slashed its 2022 profit outlook on Thursday, noting hospital and dollar challenges. But EW stock remained muted.

Edwards Slashes 2022 Profit Outlook, Citing Hospital, Dollar Challenges

IRVINE, Calif. , Oct. 20, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2022 after the market closes on Thursday, October 27, 2022, and will host a conference call at 5:00 p.m.

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON OCTOBER 27, 2022

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Edwards Lifesciences (EW) to Report Q3 Results: Wall Street Expects Earnings Growth

Edwards Lifesciences (EW) expects full-year 2022 underlying sales growth in the mid-single-digit range on the back of strength in demand for products used in more intense surgeries.

Edwards Lifesciences (EW) TAVR Sales Strong Amid Macro Issues

Apple

Alphabet

Microsoft

Motorola Solutions

Tractor Supply

Visa

David A. Rolfe is the chief investment officer at Wedgewood Partners and has been managing Wedgewood's portfolio for 18 years.

These Are the Top 10 Holdings of David Rolfe

BOSTON , Sept. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced results from CLASP IID, the first randomized controlled trial that directly compares two contemporary transcatheter edge-to-edge repair (TEER) therapies.

EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL

News for Edwards Lifesciences Stock (EW)